Attached files
file | filename |
---|---|
8-K - VistaGen Therapeutics, Inc. | form8k-03072018_060359.htm |
Exhibit 99.1
VistaGen Therapeutics
Receives Notice of Allowance for a Key U.S. Patent Covering
Treatment of Depression with AV-101
South San Francisco, CA (March 7, 2018) – VistaGen Therapeutics
Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical
company developing new generation medicines for depression and
other central nervous system (CNS) disorders, today announced
receiving a Notice of Allowance from the U.S. Patent and Trademark
Office (USPTO) for U.S. patent application no. 15/018,219 related
to methods of treating depression with AV-101, its oral new
generation glutamatergic product candidate in Phase 2 development
for treatment of Major Depressive Disorder (MDD). When issued, the
U.S. patent will not expire until at least 2034.
"This Notice of Allowance from the USPTO is a major development,
representing one of the most significant patent applications ever
allowed to our company,” stated Shawn
Singh, Chief Executive Officer of VistaGen.
“This patent will be one of the
core components of our commercial protection strategy for AV-101 in
the U.S., the world’s largest pharmaceutical market. It will
both enhance and expand substantially our U.S. market exclusivity
for AV-101. We
are continuing to pursue additional patents for AV-101, in the U.S.
and other major pharmaceutical markets, to further fortify our
global patent portfolio for this promising CNS drug
candidate.”
About VistaGen
VistaGen
Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage
biopharmaceutical company developing new generation medicines for
depression and other CNS disorders. VistaGen's lead CNS product
candidate, AV-101, is an oral NMDA receptor glycine B antagonist in
Phase 2 development, initially as a new adjunctive treatment for
Major Depressive Disorder (MDD) patients with an inadequate
response to current FDA-approved antidepressants. AV-101's
mechanism
of action is fundamentally different from all current
antidepressants and atypical antipsychotics often used adjunctively
to augment them. Most current antidepressants target the
neurotransmitters serotonin (SSRIs) and/or norepinephrine (SNRIs)
and, if effective, take many weeks to achieve therapeutic benefits.
VistaGen's AV-101 targets glutamate, the most prevalent
neurotransmitter in the brain, and, similar to ketamine, also a
NMDA receptor antagonist, has potential to drive a paradigm shift
towards a new generation of faster-acting glutamatergic
antidepressants. AV-101 may also have the potential to treat
neuropathic pain, epilepsy, Parkinson's disease levodopa-induced
dyskinesia (PD LID), suicidal ideation and other CNS diseases and
disorders where modulation of the NMDA receptors, activation of
AMPA pathways and/or key active metabolites of AV-101 may achieve
therapeutic benefits.
For
more information, please visit www.vistagen.com
and connect with VistaGen on Twitter,
LinkedIn and
Facebook.
Forward-Looking Statements
The statements in this press release that are not historical facts
may constitute forward-looking statements that are based on current
expectations and are subject to risks and uncertainties that could
cause actual future results to differ materially from those
expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to the
successful launch, continuation and results of the NIMH’s
Phase 2 (monotherapy) and/or the Company’s planned Phase 2
(adjunctive therapy) clinical studies of AV-101 in MDD, and other
CNS diseases and disorders, including neuropathic pain and
levadopa-induced dyskinesia associated with Parkinson’s
disease therapy, protection of its intellectual property, and the
availability of substantial additional capital to support its
operations, including the AV-101 clinical development activities
described above. These and other risks and uncertainties are
identified and described in more detail in VistaGen’s filings
with the Securities and Exchange Commission (SEC). These filings
are available on the SEC’s website at www.sec.gov.
VistaGen undertakes no obligation to publicly update or revise any
forward-looking statements.
Company Contact
Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com
Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com
###